566 related articles for article (PubMed ID: 16380768)
41. Genomic differences between pure ductal carcinoma in situ of the breast and that associated with invasive disease: a calibrated aCGH study.
Iakovlev VV; Arneson NC; Wong V; Wang C; Leung S; Iakovleva G; Warren K; Pintilie M; Done SJ
Clin Cancer Res; 2008 Jul; 14(14):4446-54. PubMed ID: 18628458
[TBL] [Abstract][Full Text] [Related]
42. Chromosomal alterations associated with the transition from in situ to invasive breast cancer.
Ellsworth RE; Vertrees A; Love B; Hooke JA; Ellsworth DL; Shriver CD
Ann Surg Oncol; 2008 Sep; 15(9):2519-25. PubMed ID: 18622645
[TBL] [Abstract][Full Text] [Related]
43. [Pathological characterization of atypical ductal hyperplasia of the breast].
Hoshi K; Tokunaga M; Mochizuki M; Ohtake T; Katagata N; Wakasa H; Suzuki T
Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():36-41. PubMed ID: 7747990
[TBL] [Abstract][Full Text] [Related]
44. Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia.
Gillett CE; Lee AH; Millis RR; Barnes DM
J Pathol; 1998 Apr; 184(4):396-400. PubMed ID: 9664905
[TBL] [Abstract][Full Text] [Related]
45. Metastasis tumor antigen family proteins during breast cancer progression and metastasis in a reliable mouse model for human breast cancer.
Zhang H; Stephens LC; Kumar R
Clin Cancer Res; 2006 Mar; 12(5):1479-86. PubMed ID: 16533771
[TBL] [Abstract][Full Text] [Related]
46. Different proliferative patterns characterize different preinvasive breast lesions.
Viacava P; Naccarato AG; Bevilacqua G
J Pathol; 1999 Jul; 188(3):245-51. PubMed ID: 10419590
[TBL] [Abstract][Full Text] [Related]
47. Nipple aspirate fluid cytology in breast carcinoma.
Krishnamurthy S; Sneige N; Thompson PA; Marcy SM; Singletary SE; Cristofanilli M; Hunt KK; Kuerer HM
Cancer; 2003 Apr; 99(2):97-104. PubMed ID: 12704689
[TBL] [Abstract][Full Text] [Related]
48. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
49. Prognostic significance of glutathione S-transferase-pi in invasive breast cancer.
Huang J; Tan PH; Thiyagarajan J; Bay BH
Mod Pathol; 2003 Jun; 16(6):558-65. PubMed ID: 12808061
[TBL] [Abstract][Full Text] [Related]
50. Cell proliferation and DNA fragmentation (apoptosis) on FNABs of breast invasive ductal carcinomas and their relationship to clinicopathological variables and prognosis.
Kalogeraki AM; Antoniou ChG; Askoxylakis JP; Darivianaki BM; Stathopoulos EN; Delides GS; Tsiftsis DD
In Vivo; 2002; 16(4):271-4. PubMed ID: 12224137
[TBL] [Abstract][Full Text] [Related]
51. Risk of invasion and axillary lymph node metastasis in ductal carcinoma in situ diagnosed by core-needle biopsy.
Meijnen P; Oldenburg HS; Loo CE; Nieweg OE; Peterse JL; Rutgers EJ
Br J Surg; 2007 Aug; 94(8):952-6. PubMed ID: 17440955
[TBL] [Abstract][Full Text] [Related]
52. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
53. Breast carcinoma in women 35 years and younger: a pathological study.
Fernandopulle SM; Cher-Siangang P; Tan PH
Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742
[TBL] [Abstract][Full Text] [Related]
54. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion.
Vakkala M; Pääkkö P; Soini Y
Br J Cancer; 1999 Oct; 81(4):592-9. PubMed ID: 10574243
[TBL] [Abstract][Full Text] [Related]
55. In vivo cell kinetics in breast carcinogenesis.
Bai M; Agnantis NJ; Kamina S; Demou A; Zagorianakou P; Katsaraki A; Kanavaros P
Breast Cancer Res; 2001; 3(4):276-83. PubMed ID: 11434879
[TBL] [Abstract][Full Text] [Related]
56. Concomitant expression of epithelial-mesenchymal transition biomarkers in breast ductal carcinoma: association with progression.
Logullo AF; Nonogaki S; Pasini FS; Osório CA; Soares FA; Brentani MM
Oncol Rep; 2010 Feb; 23(2):313-20. PubMed ID: 20043090
[TBL] [Abstract][Full Text] [Related]
57. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
[TBL] [Abstract][Full Text] [Related]
58. Cytological criteria for the diagnosis of intraductal hyperplasia, ductal carcinoma in situ, and invasive carcinoma of the breast.
Bofin AM; Lydersen S; Hagmar BM
Diagn Cytopathol; 2004 Oct; 31(4):207-15. PubMed ID: 15452908
[TBL] [Abstract][Full Text] [Related]
59. Extensive apoptosis in ductal carcinoma in situ of the breast.
Bodis S; Siziopikou KP; Schnitt SJ; Harris JR; Fisher DE
Cancer; 1996 May; 77(9):1831-5. PubMed ID: 8646681
[TBL] [Abstract][Full Text] [Related]
60. The status of cyclooxygenase-2 expression in ductal carcinoma in situ lesions and invasive breast cancer correlates to cyclooxygenase-2 expression in normal breast tissue.
Leo C; Faber S; Hentschel B; Höckel M; Horn LC
Ann Diagn Pathol; 2006 Dec; 10(6):327-32. PubMed ID: 17126249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
